Blumenthal D, Causino N, Campbell E, Louis K S
Health Policy Research and Development Unit, Massachusetts General Hospital, Boston, USA.
N Engl J Med. 1996 Feb 8;334(6):368-73. doi: 10.1056/NEJM199602083340606.
Despite growing acceptance of relationships between academia and industry in the life sciences, systematic, up-to-date information about their extent and the consequences for the parties involved remains scarce. We attempted to collect information about the prevalence, magnitude, commercial benefits, and potential risks of such relationships by surveying a representative sample of life-science companies in the United States to determine their relationships with academic institutions.
We collected data by telephone from May through September 1994 from senior executives of 210 life-science companies (of 306 companies surveyed; response rate, 69 percent). The sample contained all Fortune 500 companies in the fields of agriculture, chemicals, and pharmaceuticals; all international pharmaceutical companies with sales volumes similar to those of the Fortune 500 companies; and a random sample of non-Fortune 500 companies in the life sciences drawn from multiple commercial and noncommercial directories. Both the survey instrument and the survey methods resembled those of our 1984 study of 106 biotechnology companies, allowing us to assess the evolution of relationships between academia and industry over the past decade.
Ninety percent of companies conducting life-science research in the United States had relationships involving the life sciences with an academic institution in 1994. Fifty-nine percent supported research in such institutions, providing an estimated $1.5 billion, or approximately 11.7 percent of all research-and-development funding received that year. The agreements with universities tended to be short-term and to involve small amounts, implying that most such relationships supported applied research or development. Over 60 percent of companies providing support for life-science research in universities had received patents, products, and sales as a result of those relationships. At the same time, the companies reported that their relationships with universities often included agreements to keep the results of research secret beyond the time needed to file a patent. From 1984 to 1994, the involvement of industry with academic institutions has increased, but the characteristics of the relationships have remained remarkably stable.
After more than a decade of sustained interaction, universities and industries seem to have formed durable partnerships in the life sciences, although the relationships may pose greater threats to the openness of scientific communication than universities generally acknowledge. However, industrial support for university research is much smaller in amount than federal support, and companies are unlikely to be able to compensate for sizable federal cutbacks.
尽管学术界与产业界在生命科学领域的合作关系日益被接受,但关于这种合作关系的范围及其对相关各方影响的系统、最新信息仍然匮乏。我们试图通过对美国生命科学公司的代表性样本进行调查,以收集有关这种合作关系的普遍性、规模、商业利益和潜在风险的信息,从而确定它们与学术机构的关系。
我们于1994年5月至9月通过电话收集了210家生命科学公司(共调查306家公司,回复率为69%)高级管理人员的数据。样本包括农业、化工和制药领域的所有财富500强公司;所有销售额与财富500强公司相当的国际制药公司;以及从多个商业和非商业名录中抽取的生命科学领域非财富500强公司的随机样本。调查工具和调查方法与我们1984年对106家生物技术公司的研究相似,使我们能够评估过去十年学术界与产业界关系的演变。
1994年,在美国开展生命科学研究的公司中有90%与学术机构存在涉及生命科学的合作关系。59%的公司为这些机构的研究提供支持,提供了约15亿美元,约占当年所有研发资金的11.7%。与大学的协议往往是短期的,涉及金额较小,这意味着大多数此类合作关系支持应用研究或开发。在为大学的生命科学研究提供支持的公司中,超过60%的公司因这些合作关系获得了专利、产品和销售收益。与此同时,这些公司报告称,它们与大学的合作关系通常包括协议,即在申请专利所需时间之后仍对研究结果保密。从1984年到1994年,产业界与学术机构的合作有所增加,但合作关系的特点保持显著稳定。
经过十多年的持续互动,大学和产业界似乎在生命科学领域形成了持久的合作关系,尽管这种关系可能对科学交流的开放性构成比大学通常所承认的更大威胁。然而,产业界对大学研究的支持金额远低于联邦政府的支持,而且公司不太可能弥补联邦政府大幅削减的资金。